Summary

The global neurology contract research organization market is projected to be valued at US$ 9.6 Bn in 2025 and is anticipated to reach US$ 15.5 Bn by 2032, growing at a steady CAGR of 7.08% during the forecast period. This growth is fueled by the increasing burden of neurological diseases worldwide and the rising demand for specialized research support. As clinical trials become more complex and costly, pharmaceutical and biotech companies are increasingly outsourcing their neurology-focused studies to CROs with the expertise, infrastructure, and global reach needed to accelerate development timelines.


Neurology Contract Research Organization Market – Report Scope:

The neurology CRO market covers a wide range of outsourced services that support clinical and regulatory needs in neurology drug development. These services include early-phase clinical research, late-stage trials, data management, medical writing, pharmacovigilance, and regulatory consulting. CROs cater to a broad spectrum of neurological indications such as Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, and stroke. Growing reliance on external partners for managing complex CNS trials, coupled with increasing R&D budgets and technological advancements, is driving sustained expansion of the market.


Market Growth Drivers:

The market is primarily driven by the growing prevalence of neurological and neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and epilepsy. As pharmaceutical companies intensify efforts to develop effective CNS therapies, they are increasingly turning to CROs for specialized clinical trial support. The complexity and duration of neurology trials demand expertise in patient recruitment, imaging technologies, and biomarker analysis—areas where CROs excel. Furthermore, increasing regulatory requirements and the need for cost optimization are pushing sponsors to leverage CRO partnerships to streamline research and accelerate time-to-market.


Market Restraints:

Despite strong demand, the neurology CRO market faces several challenges. High trial costs, especially for studies involving imaging or long-term patient follow-up, can limit opportunities for smaller sponsors. Patient recruitment in neurological studies remains difficult due to stringent eligibility criteria and high dropout rates. A global shortage of qualified neurologists and research professionals further hinders trial execution. Moreover, variations in regulatory frameworks across countries and data privacy issues create additional hurdles for multinational neurology studies.


Market Opportunities:

Ample opportunities lie in the development of novel therapies for rare and orphan neurological diseases such as progressive muscular atrophy (PMA) and cerebral adrenoleukodystrophy (CALD). Increasing investment in gene and cell therapies is creating demand for highly specialized neurology CROs. Technological advancements such as digital therapeutics, virtual trials, and AI-based analytics are opening new frontiers for trial optimization. Additionally, rapid expansion in emerging markets across Asia Pacific and Latin America—driven by growing patient populations, lower trial costs, and favorable regulatory reforms—offers promising avenues for market growth.


Regional Outlook:

North America leads the global market, driven by a robust clinical research infrastructure, extensive R&D funding, and a high incidence of neurological conditions. The U.S. remains a key hub for neurology trials, supported by favorable FDA guidance and established CRO networks. Europe holds a strong position, with countries like Germany and the UK offering mature trial environments and growing biotech ecosystems. Asia Pacific is expected to witness the fastest growth, led by China and India, due to lower costs, expanding healthcare access, and rising clinical research investments. Latin America and the Middle East & Africa are also gaining momentum with gradual improvements in regulatory frameworks and trial capabilities.


Leading Companies:

Key players in the neurology CRO market are focusing on expanding service capabilities, investing in neuroscience expertise, and forming partnerships with biopharma innovators. Companies such as Charles River Laboratories, IQVIA Inc., and ICON plc are leading the way with integrated service offerings and global trial execution capabilities. Niche providers like Neuroservices Alliance, QPS Neuropharmacology, and Neuron Experts are differentiating themselves with deep specialization in CNS studies. Strategic collaborations with academic institutes and technology providers are helping companies strengthen their positioning in this high-growth segment.


Companies Covered in This Report:

• Charles River Laboratories

• Laboratory Corporation of America Holdings

• IQVIA Inc.

• Parexel International Corporation

• ICON plc

• Medpace

• Syneos Health

• Thermo Fisher Scientific (PPD Inc.)

• Pharmaron Beijing Co., Ltd.

• Neuroservices Alliance

• QPS Neuropharmacology

• MD Biosciences

• CTI Clinical Trial and Consulting Services

• Atlantic Research Group, Inc.

• EphyX Neuroscience

• Ergomed PLC

• Neuron Experts

• Axon CRO


Market Segmentation:

By Service:

• Clinical Services (Early Phase to Late Phase Trials)

• 510(k), IDE, IND, PMA, De Novo, and Retrospective Studies

• Data Management & Biostatistics

• Medical Writing

• Drug Safety & Pharmacovigilance

• Regulatory Affairs

• Quality and Compliance

• Pharmacology and Toxicology

By Study Type:

• Neuroscience Focused

• Neurology Focused

By Indication:

• Alzheimer’s Disease

• Brain Tumors

• Epilepsy & Seizures

• Headaches

• Schizophrenia

• Depressive Disorder

• Multiple Sclerosis (MS)

• Muscular Dystrophy

• Parkinson’s Disease

• Progressive Muscular Atrophy (PMA)

• Stroke

• Psychiatry

• Autism Spectrum Disorder

• Cerebral Adrenoleukodystrophy (CALD)

• Sleep Apnea/Sleep Dysfunction

By End User:

• Pharmaceutical & Biopharmaceutical Companies

• Medical Device Companies

• Academic and Research Institutes

By Region:

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Neurology Contract Research Organization Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Neurology Contract Research Organization Market Outlook, 2018 – 2031
3.1. Global Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Clinical Services
3.1.1.1.1. Early Phase/Phase I Development
3.1.1.1.2. Phase IIB-III Clinical Trials
3.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
3.1.1.1.4. 510(k) Clinical Studies
3.1.1.1.5. IDE Clinical Studies
3.1.1.1.6. IND Clinical Studies
3.1.1.1.7. PMA Clinical Studies
3.1.1.1.8. De Novo Clinical Studies
3.1.1.1.9. Retrospective Clinical Studies
3.1.1.2. Data Management Services
3.1.1.2.1. Clinical Database Selection
3.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
3.1.1.2.3. Clinical Site Budget Development
3.1.1.2.4. Data Management (DM) and Biostatistics (BS)
3.1.1.3. Drug Safety
3.1.1.4. Medical and Scientific Writing
3.1.1.5. Regulatory Affairs
3.1.1.6. Pharmacology and Toxicology
3.1.1.7. Quality and Compliance
3.2. Global Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Neuroscience focused.
3.2.1.2. Neurology focused.
3.3. Global Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Alzheimer's Disease
3.3.1.2. Brain Tumors
3.3.1.3. Epilepsy & Seizures
3.3.1.4. Headaches
3.3.1.5. Schizophrenia
3.3.1.6. Depressive Disorder
3.3.1.7. Multiple Sclerosis (MS)
3.3.1.8. Muscular Dystrophy
3.3.1.9. Parkinson's Disease
3.3.1.10. Progressive Muscular Atrophy (PMA)
3.3.1.11. Stroke
3.3.1.12. Psychiatry
3.3.1.13. Autism Spectrum Disorder
3.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
3.3.1.15. Sleep Apnea/ Sleep Dysfunction
3.4. Global Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. Pharmaceutical & Biopharmaceutical Companies
3.4.1.2. Biopharmaceutical Companies
3.4.1.3. Medical Device Companies
3.4.1.4. Academic and Research Institutes
3.5. Global Neurology Contract Research Organization Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Neurology Contract Research Organization Market Outlook, 2018 – 2031
4.1. North America Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Clinical Services
4.1.1.1.1. Early Phase/Phase I Development
4.1.1.1.2. Phase IIB-III Clinical Trials
4.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
4.1.1.1.4. 510(k) Clinical Studies
4.1.1.1.5. IDE Clinical Studies
4.1.1.1.6. IND Clinical Studies
4.1.1.1.7. PMA Clinical Studies
4.1.1.1.8. De Novo Clinical Studies
4.1.1.1.9. Retrospective Clinical Studies
4.1.1.2. Data Management Services
4.1.1.2.1. Clinical Database Selection
4.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
4.1.1.2.3. Clinical Site Budget Development
4.1.1.2.4. Data Management (DM) and Biostatistics (BS)
4.1.1.3. Drug Safety
4.1.1.4. Medical and Scientific Writing
4.1.1.5. Regulatory Affairs
4.1.1.6. Pharmacology and Toxicology
4.1.1.7. Quality and Compliance
4.2. North America Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Neuroscience focused.
4.2.1.2. Neurology focused.
4.3. North America Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Alzheimer's Disease
4.3.1.2. Brain Tumors
4.3.1.3. Epilepsy & Seizures
4.3.1.4. Headaches
4.3.1.5. Schizophrenia
4.3.1.6. Depressive Disorder
4.3.1.7. Multiple Sclerosis (MS)
4.3.1.8. Muscular Dystrophy
4.3.1.9. Parkinson's Disease
4.3.1.10. Progressive Muscular Atrophy (PMA)
4.3.1.11. Stroke
4.3.1.12. Psychiatry
4.3.1.13. Autism Spectrum Disorder
4.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
4.3.1.15. Sleep Apnea/ Sleep Dysfunction
4.4. North America Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. Pharmaceutical & Biopharmaceutical Companies
4.4.1.2. Biopharmaceutical Companies
4.4.1.3. Medical Device Companies
4.4.1.4. Academic and Research Institutes
4.5. North America Neurology Contract Research Organization Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
4.5.1.2. U.S. Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
4.5.1.3. U.S. Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
4.5.1.4. U.S. Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
4.5.1.5. Canada Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
4.5.1.6. Canada Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
4.5.1.7. Canada Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
4.5.1.8. Canada Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Neurology Contract Research Organization Market Outlook, 2018 – 2031
5.1. Europe Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Clinical Services
5.1.1.1.1. Early Phase/Phase I Development
5.1.1.1.2. Phase IIB-III Clinical Trials
5.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
5.1.1.1.4. 510(k) Clinical Studies
5.1.1.1.5. IDE Clinical Studies
5.1.1.1.6. IND Clinical Studies
5.1.1.1.7. PMA Clinical Studies
5.1.1.1.8. De Novo Clinical Studies
5.1.1.1.9. Retrospective Clinical Studies
5.1.1.2. Data Management Services
5.1.1.2.1. Clinical Database Selection
5.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
5.1.1.2.3. Clinical Site Budget Development
5.1.1.2.4. Data Management (DM) and Biostatistics (BS)
5.1.1.3. Drug Safety
5.1.1.4. Medical and Scientific Writing
5.1.1.5. Regulatory Affairs
5.1.1.6. Pharmacology and Toxicology
5.1.1.7. Quality and Compliance
5.2. Europe Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Neuroscience focused.
5.2.1.2. Neurology focused.
5.3. Europe Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Alzheimer's Disease
5.3.1.2. Brain Tumors
5.3.1.3. Epilepsy & Seizures
5.3.1.4. Headaches
5.3.1.5. Schizophrenia
5.3.1.6. Depressive Disorder
5.3.1.7. Multiple Sclerosis (MS)
5.3.1.8. Muscular Dystrophy
5.3.1.9. Parkinson's Disease
5.3.1.10. Progressive Muscular Atrophy (PMA)
5.3.1.11. Stroke
5.3.1.12. Psychiatry
5.3.1.13. Autism Spectrum Disorder
5.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
5.3.1.15. Sleep Apnea/ Sleep Dysfunction
5.4. Europe Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Pharmaceutical & Biopharmaceutical Companies
5.4.1.2. Biopharmaceutical Companies
5.4.1.3. Medical Device Companies
5.4.1.4. Academic and Research Institutes
5.5. Europe Neurology Contract Research Organization Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.5.1. Key Highlights
5.5.1.1. Germany Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.2. Germany Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.3. Germany Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.4. Germany Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.5. U.K. Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.6. U.K. Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.7. U.K. Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.8. U.K. Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.9. France Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.10. France Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.11. France Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.12. France Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.13. Italy Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.14. Italy Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.15. Italy Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.16. Italy Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.17. Turkey Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.18. Turkey Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.19. Turkey Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.20. Turkey Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.21. Russia Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.22. Russia Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.23. Russia Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.24. Russia Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.1.25. Rest of Europe Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
5.5.1.26. Rest of Europe Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
5.5.1.27. Rest of Europe Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
5.5.1.28. Rest of Europe Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Neurology Contract Research Organization Market Outlook, 2018 – 2031
6.1. Asia Pacific Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Clinical Services
6.1.1.1.1. Early Phase/Phase I Development
6.1.1.1.2. Phase IIB-III Clinical Trials
6.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
6.1.1.1.4. 510(k) Clinical Studies
6.1.1.1.5. IDE Clinical Studies
6.1.1.1.6. IND Clinical Studies
6.1.1.1.7. PMA Clinical Studies
6.1.1.1.8. De Novo Clinical Studies
6.1.1.1.9. Retrospective Clinical Studies
6.1.1.2. Data Management Services
6.1.1.2.1. Clinical Database Selection
6.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
6.1.1.2.3. Clinical Site Budget Development
6.1.1.2.4. Data Management (DM) and Biostatistics (BS)
6.1.1.3. Drug Safety
6.1.1.4. Medical and Scientific Writing
6.1.1.5. Regulatory Affairs
6.1.1.6. Pharmacology and Toxicology
6.1.1.7. Quality and Compliance
6.2. Asia Pacific Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Neuroscience focused.
6.2.1.2. Neurology focused.
6.3. Asia Pacific Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Alzheimer's Disease
6.3.1.2. Brain Tumors
6.3.1.3. Epilepsy & Seizures
6.3.1.4. Headaches
6.3.1.5. Schizophrenia
6.3.1.6. Depressive Disorder
6.3.1.7. Multiple Sclerosis (MS)
6.3.1.8. Muscular Dystrophy
6.3.1.9. Parkinson's Disease
6.3.1.10. Progressive Muscular Atrophy (PMA)
6.3.1.11. Stroke
6.3.1.12. Psychiatry
6.3.1.13. Autism Spectrum Disorder
6.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
6.3.1.15. Sleep Apnea/ Sleep Dysfunction
6.4. Asia Pacific Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. Pharmaceutical & Biopharmaceutical Companies
6.4.1.2. Biopharmaceutical Companies
6.4.1.3. Medical Device Companies
6.4.1.4. Academic and Research Institutes
6.5. Asia Pacific Neurology Contract Research Organization Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.5.1. Key Highlights
6.5.1.1. China Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.2. China Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.3. China Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.4. China Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.1.5. Japan Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.6. Japan Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.7. Japan Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.8. Japan Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.1.9. South Korea Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.10. South Korea Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.11. South Korea Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.12. South Korea Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.1.13. India Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.14. India Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.15. India Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.16. India Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.1.17. Southeast Asia Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.18. Southeast Asia Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.19. Southeast Asia Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.20. Southeast Asia Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.1.21. Rest of Asia Pacific Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
6.5.1.22. Rest of Asia Pacific Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
6.5.1.23. Rest of Asia Pacific Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
6.5.1.24. Rest of Asia Pacific Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Neurology Contract Research Organization Market Outlook, 2018 – 2031
7.1. Latin America Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Clinical Services
7.1.1.1.1. Early Phase/Phase I Development
7.1.1.1.2. Phase IIB-III Clinical Trials
7.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
7.1.1.1.4. 510(k) Clinical Studies
7.1.1.1.5. IDE Clinical Studies
7.1.1.1.6. IND Clinical Studies
7.1.1.1.7. PMA Clinical Studies
7.1.1.1.8. De Novo Clinical Studies
7.1.1.1.9. Retrospective Clinical Studies
7.1.1.2. Data Management Services
7.1.1.2.1. Clinical Database Selection
7.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
7.1.1.2.3. Clinical Site Budget Development
7.1.1.2.4. Data Management (DM) and Biostatistics (BS)
7.1.1.3. Drug Safety
7.1.1.4. Medical and Scientific Writing
7.1.1.5. Regulatory Affairs
7.1.1.6. Pharmacology and Toxicology
7.1.1.7. Quality and Compliance
7.2. Latin America Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Neuroscience focused.
7.2.1.2. Neurology focused.
7.3. Latin America Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Alzheimer's Disease
7.3.1.2. Brain Tumors
7.3.1.3. Epilepsy & Seizures
7.3.1.4. Headaches
7.3.1.5. Schizophrenia
7.3.1.6. Depressive Disorder
7.3.1.7. Multiple Sclerosis (MS)
7.3.1.8. Muscular Dystrophy
7.3.1.9. Parkinson's Disease
7.3.1.10. Progressive Muscular Atrophy (PMA)
7.3.1.11. Stroke
7.3.1.12. Psychiatry
7.3.1.13. Autism Spectrum Disorder
7.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
7.3.1.15. Sleep Apnea/ Sleep Dysfunction
7.4. Latin America Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Pharmaceutical & Biopharmaceutical Companies
7.4.1.2. Biopharmaceutical Companies
7.4.1.3. Medical Device Companies
7.4.1.4. Academic and Research Institutes
7.5. Latin America Neurology Contract Research Organization Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
7.5.1.2. Brazil Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
7.5.1.3. Brazil Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
7.5.1.4. Brazil Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
7.5.1.5. Mexico Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
7.5.1.6. Mexico Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
7.5.1.7. Mexico Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
7.5.1.8. Mexico Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
7.5.1.9. Argentina Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
7.5.1.10. Argentina Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
7.5.1.11. Argentina Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
7.5.1.12. Argentina Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
7.5.1.13. Rest of Latin America Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
7.5.1.14. Rest of Latin America Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
7.5.1.15. Rest of Latin America Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
7.5.1.16. Rest of Latin America Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Neurology Contract Research Organization Market Outlook, 2018 – 2031
8.1. Middle East & Africa Neurology Contract Research Organization Market Outlook, by Service, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Clinical Services
8.1.1.1.1. Early Phase/Phase I Development
8.1.1.1.2. Phase IIB-III Clinical Trials
8.1.1.1.3. Phase IIIB-Phase IV Clinical Trials
8.1.1.1.4. 510(k) Clinical Studies
8.1.1.1.5. IDE Clinical Studies
8.1.1.1.6. IND Clinical Studies
8.1.1.1.7. PMA Clinical Studies
8.1.1.1.8. De Novo Clinical Studies
8.1.1.1.9. Retrospective Clinical Studies
8.1.1.2. Data Management Services
8.1.1.2.1. Clinical Database Selection
8.1.1.2.2. Clinical Study Planning and Clinical Protocol Development
8.1.1.2.3. Clinical Site Budget Development
8.1.1.2.4. Data Management (DM) and Biostatistics (BS)
8.1.1.3. Drug Safety
8.1.1.4. Medical and Scientific Writing
8.1.1.5. Regulatory Affairs
8.1.1.6. Pharmacology and Toxicology
8.1.1.7. Quality and Compliance
8.2. Middle East & Africa Neurology Contract Research Organization Market Outlook, by Study, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Neuroscience focused.
8.2.1.2. Neurology focused.
8.3. Middle East & Africa Neurology Contract Research Organization Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Alzheimer's Disease
8.3.1.2. Brain Tumors
8.3.1.3. Epilepsy & Seizures
8.3.1.4. Headaches
8.3.1.5. Schizophrenia
8.3.1.6. Depressive Disorder
8.3.1.7. Multiple Sclerosis (MS)
8.3.1.8. Muscular Dystrophy
8.3.1.9. Parkinson's Disease
8.3.1.10. Progressive Muscular Atrophy (PMA)
8.3.1.11. Stroke
8.3.1.12. Psychiatry
8.3.1.13. Autism Spectrum Disorder
8.3.1.14. Cerebral Adrenoleukodystrophy (CALD)
8.3.1.15. Sleep Apnea/ Sleep Dysfunction
8.4. Middle East & Africa Neurology Contract Research Organization Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. Pharmaceutical & Biopharmaceutical Companies
8.4.1.2. Biopharmaceutical Companies
8.4.1.3. Medical Device Companies
8.4.1.4. Academic and Research Institutes
8.5. Middle East & Africa Neurology Contract Research Organization Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.5.1. Key Highlights
8.5.1.1. GCC Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
8.5.1.2. GCC Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
8.5.1.3. GCC Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
8.5.1.4. GCC Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
8.5.1.5. South Africa Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
8.5.1.6. South Africa Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
8.5.1.7. South Africa Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
8.5.1.8. South Africa Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
8.5.1.9. Egypt Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
8.5.1.10. Egypt Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
8.5.1.11. Egypt Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
8.5.1.12. Egypt Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
8.5.1.13. Nigeria Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
8.5.1.14. Nigeria Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
8.5.1.15. Nigeria Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
8.5.1.16. Nigeria Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
8.5.1.17. Rest of Middle East & Africa Neurology Contract Research Organization Market by Service, Value (US$ Bn), 2018 – 2031
8.5.1.18. Rest of Middle East & Africa Neurology Contract Research Organization Market Indication, Value (US$ Bn), 2018 – 2031
8.5.1.19. Rest of Middle East & Africa Neurology Contract Research Organization Market Artery Type, Value (US$ Bn), 2018 – 2031
8.5.1.20. Rest of Middle East & Africa Neurology Contract Research Organization Market End User, Value (US$ Bn), 2018 – 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Artery Type vs Indication Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Charles River Laboratories
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Laboratory Corporation of America Holdings
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. IQVIA Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Syneos Health
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Parexel International Corporation
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. ICON Plc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Medpace
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Axon CRO
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Thermo Fisher Scientific Inc. (PPD Inc.)
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. CTI Clinical Trial & Consulting
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Pharmaron Beijing Co., Ltd.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Neuroservices-Alliance
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. QPS Neuropharmacology
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. MD Biosciences
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.15. Atlantic Research Group, Inc.
9.5.15.1. Company Overview
9.5.15.2. Product Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development
9.5.16. EphyX Neuroscience
9.5.16.1. Company Overview
9.5.16.2. Product Portfolio
9.5.16.3. Financial Overview
9.5.16.4. Business Strategies and Development
9.5.17. Ergomed plc
9.5.17.1. Company Overview
9.5.17.2. Product Portfolio
9.5.17.3. Financial Overview
9.5.17.4. Business Strategies and Development
9.5.18. Neuron Experts
9.5.18.1. Company Overview
9.5.18.2. Product Portfolio
9.5.18.3. Financial Overview
9.5.18.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations